City of Hope | Strategic Alliance Partners

April 07, 2015

For further insight into the evolving role of expanded mutation analysis in mCRC, OncLive interviewed Marwan G. Fakih, MD, the director of Gastrointestinal Medical Oncology at City of Hope.

March 18, 2015

Recent advancements in the treatment of ovarian cancer, including surgical techniques, the approvals of bevacizumab and olaparib, and intraperitoneal chemotherapy, have led the National Comprehensive Cancer Network to make changes to their clinical practice guidelines.

January 15, 2015

Joseph Alvarnas, MD, the director of Medical Quality at City of Hope National Medical Center, discusses autologous hematopoietic stem cell transplantation (AHCT) for patients with HIV-associated lymphoma.

December 14, 2014

Surgery remains the most effective curative treatment for esophageal cancer. Yet, many eligible patients do not undergo esophagectomy.

July 28, 2014

Karen L. Reckamp, MD, discusses the results of a phase II study of the AKT inhibitor MK-2206 plus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who progressed on erlotinib.

July 22, 2014

Cabozantinib added to erlotinib has antitumor activity in heavily pretreated patients with EGFR-positive non–small cell lung cancer (NSCLC) whose disease progressed on erlotinib alone, according to the results of a phase II trial presented at the 2014 ASCO Annual Meeting.

April 23, 2014

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses the results of a retrospective analysis of the effect of prior abiraterone use on the activity level of enzalutamide in men with metastatic castration-resistant prostate cancer (mCRPC).

February 25, 2014

Marwan G. Fakih, MD, professor, director, Gastrointestinal Medical Oncology, City of Hope, discusses anti-angiogenesis versus anti-EGFR therapy in patients who have RAS wild-type colorectal cancer.

December 03, 2013

Both men and women report a significant decline in sexual satisfaction after hematopoietic cell transplantation that is sustained at 3-year follow-up.

November 19, 2013

Over the past few years, seven new drugs have gained approval from the FDA for the treatment of patients with metastatic renal cell carcinoma. Primarily these approaches target angiogenesis and mTOR. The advent of these molecularly targeted therapies has significantly improved the standard of care for patients with RCC.

November 13, 2013

Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy of renal cell carcinoma (RCC).

July 30, 2013

Patients diagnosed with cancer today are considered to be genuine partners in all major treatment decisions. Yet, how well do they understand the nature and goals of genetic testing that might be recommended as part of the management of their disease?

March 01, 2013

Despite all we have learned about the importance of sensitizing EGFR mutations in defining the management of advanced NSCLC, our education regarding the relevance of this molecular target in optimizing clinical outcomes continues.

February 06, 2013

Maurie Markman, MD, asks who should decide whether it is ethically valid to consider off-label treatment in a patient with a very serious medical illness.

January 04, 2013

In the absence of a phase III randomized trial, what constitutes sufficient evidence to justify use of a treatment, particularly a nontraditional treatment or one that challenges common practice?

November 26, 2012

Jeffrey N. Weitzel, MD, from City of Hope, discusses the need to develop combination strategies for patients with breast cancer, in order to overcome the resistance.

August 22, 2011

Dr. Karen Reckamp City of Hope cancer center on Current Heat Shock Protein Clinical Trials

August 19, 2011

Dr. Karen Reckamp from City of Hope Cancer Center Describes the Use of Heat Shock Proteins

May 18, 2011

Dr. Markman on Taxane-Induced Neuropathy Biomarkers

March 22, 2011

A subgroup analysis of a randomized trial showed that patients with previously treated metastatic renal cell carcinoma had significant improvement in progression-free survival when they received everolimus.